With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study Meeting Abstract
| Authors: | Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; DeAngelo, D. J.; Lang, F.; Heinrich, M. C.; De Soria, V. G. G.; le Coutre, P.; Sanchez-Olle, G.; Jose, J.; Pognan, N.; Kapoor, S.; Rea, D. |
| Abstract Title: | With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 450 |
| Language: | English |
| ACCESSION: | WOS:001159306701207 |
| DOI: | 10.1182/blood-2023-187322 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
